Tuesday’s HotCopper trends: Neuren Pharma, Resolution, Solstice, and other daily topics | Feb 3

Core Insights - Neuren Pharmaceuticals (ASX:NEU) is facing a negative trend vote from the EU Medicines Agency's Committee regarding its licensee Acadia's trofinetide marketing, leading to a 10% drop in NEU shares [2][3] - Resolution Minerals (ASX:RML) has seen a 4% increase in share price due to positive developments related to its Nasdaq registration statement submitted to the U.S. Securities and Exchange Commission [3][4] - Solstice Minerals (ASX:SLS) reported outstanding high-grade copper-gold intercepts at its Nanadie Project, resulting in a significant 49% increase in SLS shares [4][5] Company Summaries - Neuren Pharmaceuticals is currently seeking a re-vote after the negative trend vote, which has impacted its stock performance [3] - Resolution Minerals is progressing towards joining the Wall Street race with its recent SEC registration statement, with pending results expected [4] - Solstice Minerals has commenced drilling at its WA dig-site, achieving promising results that have positively influenced its stock price [4][5] Market Trends - The overall ASX market has experienced a 1.2% increase, reflecting broader market movements alongside individual stock performances [5]